484 related articles for article (PubMed ID: 32594286)
21. Potential Disparities by Sex and Race or Ethnicity in Lung Cancer Screening Eligibility Rates.
Pinsky PF; Lau YK; Doubeni CA
Chest; 2021 Jul; 160(1):341-350. PubMed ID: 33545164
[TBL] [Abstract][Full Text] [Related]
22. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.
de Koning HJ; Meza R; Plevritis SK; ten Haaf K; Munshi VN; Jeon J; Erdogan SA; Kong CY; Han SS; van Rosmalen J; Choi SE; Pinsky PF; Berrington de Gonzalez A; Berg CD; Black WC; Tammemägi MC; Hazelton WD; Feuer EJ; McMahon PM
Ann Intern Med; 2014 Mar; 160(5):311-20. PubMed ID: 24379002
[TBL] [Abstract][Full Text] [Related]
23. Analysis of lung cancer risk model (PLCO
Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
[TBL] [Abstract][Full Text] [Related]
24. Performance of Risk Factor-Based Guidelines and Model-Based Chest CT Lung Cancer Screening in World Trade Center-Exposed Fire Department Rescue/Recovery Workers.
Cleven KL; Vaeth B; Zeig-Owens R; Colbeth HL; Jaber N; Schwartz T; Weiden MD; Markowitz SB; Silvestri GA; Prezant DJ
Chest; 2021 May; 159(5):2060-2071. PubMed ID: 33279511
[TBL] [Abstract][Full Text] [Related]
25. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients.
Walter J; Kauffmann-Guerrero D; Muley T; Reck M; Fuge J; Günther A; Majeed RW; Savai R; Koch I; Dinkel J; Schneider C; Senghas K; Kobinger S; Manapov F; Thomas M; Kahnert K; Winter H; Behr J; Tammemägi M; Tufman A
Cancer Med; 2023 Apr; 12(7):8880-8896. PubMed ID: 36707972
[TBL] [Abstract][Full Text] [Related]
27. Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model.
Chien LH; Chen CH; Chen TY; Chang GC; Tsai YH; Hsiao CF; Chen KY; Su WC; Wang WC; Huang MS; Chen YM; Chen CY; Liang SK; Chen CY; Wang CL; Lee MH; Chung RH; Tsai FY; Hu JW; Katki HA; Chatterjee N; Chanock SJ; Rothman N; Lan Q; Yang PC; Chen CJ; Chang IS; Hsiung CA
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):452-459. PubMed ID: 31848206
[TBL] [Abstract][Full Text] [Related]
28. Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review.
Williams RM; Kareff SA; Sackstein P; Roy T; Luta G; Kim C; Taylor KL; Tammemägi MC
Lung Cancer; 2022 Jul; 169():55-60. PubMed ID: 35644087
[TBL] [Abstract][Full Text] [Related]
29. Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
Choi E; Ding VY; Luo SJ; Ten Haaf K; Wu JT; Aredo JV; Wilkens LR; Freedman ND; Backhus LM; Leung AN; Meza R; Lui NS; Haiman CA; Park SL; Le Marchand L; Neal JW; Cheng I; Wakelee HA; Tammemägi MC; Han SS
JAMA Oncol; 2023 Dec; 9(12):1640-1648. PubMed ID: 37883107
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
[TBL] [Abstract][Full Text] [Related]
31. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?
Pinsky PF; Berg CD
J Med Screen; 2012 Sep; 19(3):154-6. PubMed ID: 23060474
[TBL] [Abstract][Full Text] [Related]
32. Economic impact of using risk models for eligibility selection to the International lung screening Trial.
Cressman S; Weber MF; Ngo PJ; Wade S; Behar Harpaz S; Caruana M; Tremblay A; Manser R; Stone E; Atkar-Khattra S; Karikios D; Ho C; Fernandes A; Yi Weng J; McWilliams A; Myers R; Mayo J; Yee J; Yuan R; Marshall HM; Fong KM; Lam S; Canfell K; Tammemägi MC
Lung Cancer; 2023 Feb; 176():38-45. PubMed ID: 36592498
[TBL] [Abstract][Full Text] [Related]
33. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
[TBL] [Abstract][Full Text] [Related]
34. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
[TBL] [Abstract][Full Text] [Related]
36. Screening for lung cancer: 2023 guideline update from the American Cancer Society.
Wolf AMD; Oeffinger KC; Shih TY; Walter LC; Church TR; Fontham ETH; Elkin EB; Etzioni RD; Guerra CE; Perkins RB; Kondo KK; Kratzer TB; Manassaram-Baptiste D; Dahut WL; Smith RA
CA Cancer J Clin; 2024; 74(1):50-81. PubMed ID: 37909877
[TBL] [Abstract][Full Text] [Related]
37. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
[TBL] [Abstract][Full Text] [Related]
38. Evaluating efficacy of current lung cancer screening guidelines.
Nemesure B; Plank A; Reagan L; Albano D; Reiter M; Bilfinger TV
J Med Screen; 2017 Dec; 24(4):208-213. PubMed ID: 28201949
[TBL] [Abstract][Full Text] [Related]
39. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.
Liao W; Coupland CAC; Burchardt J; Baldwin DR; ; Gleeson FV; Hippisley-Cox J
Lancet Respir Med; 2023 Aug; 11(8):685-697. PubMed ID: 37030308
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
